Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Supply, Demand and Key Producers, 2024-2030

Page: 106

Published Date: 25 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.

This report studies the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs total production and demand, 2019-2030, (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs total production value, 2019-2030, (USD Million)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs consumption by region & country, CAGR, 2019-2030 & (K MT)
U.S. VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs domestic production, consumption, key domestic manufacturers and share
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs production by Application production, value, CAGR, 2019-2030, (USD Million) & (K MT).

This reports profiles key players in the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer Healthcare, Roche, Neurotech Pharmaceuticals, Regeneron Pharmaceuticals and Allergan, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K MT) and average price (USD/MT) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market, Segmentation by Type
    Macular Degeneration Drugs
    Diabetic Retinopathy Drugs

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market, Segmentation by Application
    50-60 Years Old
    60-70 Years Old
    Others

Companies Profiled:
    Novartis
    Bayer Healthcare
    Roche
    Neurotech Pharmaceuticals
    Regeneron Pharmaceuticals
    Allergan

Key Questions Answered
1. How big is the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market?
2. What is the demand of the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market?
3. What is the year over year growth of the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market?
4. What is the production and production value of the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market?
5. Who are the key producers in the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market?

Table of Contents

1 Supply Summary
    1.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
    1.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Supply & Forecast
        1.2.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value (2019 & 2023 & 2030)
        1.2.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.2.3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Pricing Trends (2019-2030)
    1.3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Region (Based on Production Site)
        1.3.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Region (2019-2030)
        1.3.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Region (2019-2030)
        1.3.3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Region (2019-2030)
        1.3.4 North America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.3.5 Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.3.6 China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.3.7 Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.3.8 Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.3.9 India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
        1.3.10 Central & South America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Market Trends

2 Demand Summary
    2.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Demand (2019-2030)
    2.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption by Region
        2.2.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption by Region (2019-2024)
        2.2.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast by Region (2025-2030)
    2.3 United States Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)
    2.4 China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)
    2.5 Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)
    2.6 Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)
    2.7 South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)
    2.8 ASEAN Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)
    2.9 India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030)

3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers Competitive Analysis
    3.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Manufacturer (2019-2024)
    3.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Manufacturer (2019-2024)
    3.3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Manufacturer (2019-2024)
    3.4 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs in 2023
        3.5.3 Global Concentration Ratios (CR8) for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs in 2023
    3.6 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Overall Company Footprint Analysis
        3.6.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Region Footprint
        3.6.2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Company Product Type Footprint
        3.6.3 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Comparison
        4.1.1 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Comparison (2019 & 2023 & 2030)
        4.1.2 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Comparison
        4.2.1 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Comparison
        4.3.1 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Comparison (2019 & 2023 & 2030)
        4.3.2 United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Market Share Comparison (2019 & 2023 & 2030)
    4.4 United States Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers and Market Share, 2019-2024
        4.4.1 United States Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value (2019-2024)
        4.4.3 United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2024)
    4.5 China Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers and Market Share
        4.5.1 China Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value (2019-2024)
        4.5.3 China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2024)
    4.6 Rest of World Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers and Market Share, 2019-2024
        4.6.1 Rest of World Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value (2019-2024)
        4.6.3 Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2024)

5 Market Analysis by Type
    5.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Macular Degeneration Drugs
        5.2.2 Diabetic Retinopathy Drugs
    5.3 Market Segment by Type
        5.3.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Type (2019-2030)
        5.3.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Type (2019-2030)
        5.3.3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 50-60 Years Old
        6.2.2 60-70 Years Old
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Application (2019-2030)
        6.3.2 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Application (2019-2030)
        6.3.3 World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Application (2019-2030)

7 Company Profiles
    7.1 Novartis
        7.1.1 Novartis Details
        7.1.2 Novartis Major Business
        7.1.3 Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
        7.1.4 Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.1.5 Novartis Recent Developments/Updates
        7.1.6 Novartis Competitive Strengths & Weaknesses
    7.2 Bayer Healthcare
        7.2.1 Bayer Healthcare Details
        7.2.2 Bayer Healthcare Major Business
        7.2.3 Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
        7.2.4 Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.2.5 Bayer Healthcare Recent Developments/Updates
        7.2.6 Bayer Healthcare Competitive Strengths & Weaknesses
    7.3 Roche
        7.3.1 Roche Details
        7.3.2 Roche Major Business
        7.3.3 Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
        7.3.4 Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.3.5 Roche Recent Developments/Updates
        7.3.6 Roche Competitive Strengths & Weaknesses
    7.4 Neurotech Pharmaceuticals
        7.4.1 Neurotech Pharmaceuticals Details
        7.4.2 Neurotech Pharmaceuticals Major Business
        7.4.3 Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
        7.4.4 Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.4.5 Neurotech Pharmaceuticals Recent Developments/Updates
        7.4.6 Neurotech Pharmaceuticals Competitive Strengths & Weaknesses
    7.5 Regeneron Pharmaceuticals
        7.5.1 Regeneron Pharmaceuticals Details
        7.5.2 Regeneron Pharmaceuticals Major Business
        7.5.3 Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
        7.5.4 Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
        7.5.6 Regeneron Pharmaceuticals Competitive Strengths & Weaknesses
    7.6 Allergan
        7.6.1 Allergan Details
        7.6.2 Allergan Major Business
        7.6.3 Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
        7.6.4 Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production, Price, Value, Gross Margin and Market Share (2019-2024)
        7.6.5 Allergan Recent Developments/Updates
        7.6.6 Allergan Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Chain
    8.2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Upstream Analysis
        8.2.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Core Raw Materials
        8.2.2 Main Manufacturers of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Mode
    8.6 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Procurement Model
    8.7 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Sales Model and Sales Channels
        8.7.1 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Model
        8.7.2 Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Region (2019, 2023 and 2030) & (USD Million)
    Table 2. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Region (2019-2024) & (USD Million)
    Table 3. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Region (2025-2030) & (USD Million)
    Table 4. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Region (2019-2024)
    Table 5. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Region (2025-2030)
    Table 6. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Region (2019-2024) & (K MT)
    Table 7. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Region (2025-2030) & (K MT)
    Table 8. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share by Region (2019-2024)
    Table 9. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share by Region (2025-2030)
    Table 10. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Region (2019-2024) & (USD/MT)
    Table 11. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Region (2025-2030) & (USD/MT)
    Table 12. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Major Market Trends
    Table 13. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K MT)
    Table 14. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption by Region (2019-2024) & (K MT)
    Table 15. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Forecast by Region (2025-2030) & (K MT)
    Table 16. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Manufacturer (2019-2024) & (USD Million)
    Table 17. Production Value Market Share of Key Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Producers in 2023
    Table 18. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Manufacturer (2019-2024) & (K MT)
    Table 19. Production Market Share of Key Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Producers in 2023
    Table 20. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Manufacturer (2019-2024) & (USD/MT)
    Table 21. Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Company Evaluation Quadrant
    Table 22. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2023
    Table 23. Head Office and Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Site of Key Manufacturer
    Table 24. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Company Product Type Footprint
    Table 25. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market: Company Product Application Footprint
    Table 26. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Competitive Factors
    Table 27. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs New Entrant and Capacity Expansion Plans
    Table 28. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Mergers & Acquisitions Activity
    Table 29. United States VS China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 30. United States VS China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Comparison, (2019 & 2023 & 2030) & (K MT)
    Table 31. United States VS China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Comparison, (2019 & 2023 & 2030) & (K MT)
    Table 32. United States Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value, (2019-2024) & (USD Million)
    Table 34. United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share (2019-2024)
    Table 35. United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2024) & (K MT)
    Table 36. United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share (2019-2024)
    Table 37. China Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value, (2019-2024) & (USD Million)
    Table 39. China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share (2019-2024)
    Table 40. China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2024) & (K MT)
    Table 41. China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share (2019-2024)
    Table 42. Rest of World Based Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value, (2019-2024) & (USD Million)
    Table 44. Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share (2019-2024)
    Table 45. Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2024) & (K MT)
    Table 46. Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share (2019-2024)
    Table 47. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 48. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Type (2019-2024) & (K MT)
    Table 49. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Type (2025-2030) & (K MT)
    Table 50. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Type (2019-2024) & (USD Million)
    Table 51. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Type (2025-2030) & (USD Million)
    Table 52. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Type (2019-2024) & (USD/MT)
    Table 53. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Type (2025-2030) & (USD/MT)
    Table 54. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 55. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Application (2019-2024) & (K MT)
    Table 56. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production by Application (2025-2030) & (K MT)
    Table 57. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Application (2019-2024) & (USD Million)
    Table 58. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Application (2025-2030) & (USD Million)
    Table 59. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Application (2019-2024) & (USD/MT)
    Table 60. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Application (2025-2030) & (USD/MT)
    Table 61. Novartis Basic Information, Manufacturing Base and Competitors
    Table 62. Novartis Major Business
    Table 63. Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
    Table 64. Novartis Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (K MT), Price (USD/MT), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 65. Novartis Recent Developments/Updates
    Table 66. Novartis Competitive Strengths & Weaknesses
    Table 67. Bayer Healthcare Basic Information, Manufacturing Base and Competitors
    Table 68. Bayer Healthcare Major Business
    Table 69. Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
    Table 70. Bayer Healthcare Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (K MT), Price (USD/MT), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 71. Bayer Healthcare Recent Developments/Updates
    Table 72. Bayer Healthcare Competitive Strengths & Weaknesses
    Table 73. Roche Basic Information, Manufacturing Base and Competitors
    Table 74. Roche Major Business
    Table 75. Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
    Table 76. Roche Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (K MT), Price (USD/MT), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 77. Roche Recent Developments/Updates
    Table 78. Roche Competitive Strengths & Weaknesses
    Table 79. Neurotech Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 80. Neurotech Pharmaceuticals Major Business
    Table 81. Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
    Table 82. Neurotech Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (K MT), Price (USD/MT), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 83. Neurotech Pharmaceuticals Recent Developments/Updates
    Table 84. Neurotech Pharmaceuticals Competitive Strengths & Weaknesses
    Table 85. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 86. Regeneron Pharmaceuticals Major Business
    Table 87. Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
    Table 88. Regeneron Pharmaceuticals Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (K MT), Price (USD/MT), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 89. Regeneron Pharmaceuticals Recent Developments/Updates
    Table 90. Allergan Basic Information, Manufacturing Base and Competitors
    Table 91. Allergan Major Business
    Table 92. Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product and Services
    Table 93. Allergan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (K MT), Price (USD/MT), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
    Table 94. Global Key Players of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Upstream (Raw Materials)
    Table 95. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Typical Customers
    Table 96. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Typical Distributors
List of Figure
    Figure 1. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Picture
    Figure 2. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value and Forecast (2019-2030) & (USD Million)
    Figure 4. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 5. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price (2019-2030) & (USD/MT)
    Figure 6. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Region (2019-2030)
    Figure 7. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share by Region (2019-2030)
    Figure 8. North America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 9. Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 10. China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 11. Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 12. Southeast Asia Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 13. India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 14. Central & South America Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production (2019-2030) & (K MT)
    Figure 15. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Drivers
    Figure 16. Factors Affecting Demand
    Figure 17. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 18. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Market Share by Region (2019-2030)
    Figure 19. United States Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 20. China Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 21. Europe Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 22. Japan Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 23. South Korea Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 24. ASEAN Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 25. India Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption (2019-2030) & (K MT)
    Figure 26. Producer Shipments of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
    Figure 27. Global Four-firm Concentration Ratios (CR4) for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Markets in 2023
    Figure 28. Global Four-firm Concentration Ratios (CR8) for Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Markets in 2023
    Figure 29. United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 30. United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share Comparison (2019 & 2023 & 2030)
    Figure 31. United States VS China: Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Consumption Market Share Comparison (2019 & 2023 & 2030)
    Figure 32. United States Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share 2023
    Figure 33. China Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share 2023
    Figure 34. Rest of World Based Manufacturers Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share 2023
    Figure 35. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 36. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Type in 2023
    Figure 37. Macular Degeneration Drugs
    Figure 38. Diabetic Retinopathy Drugs
    Figure 39. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share by Type (2019-2030)
    Figure 40. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Type (2019-2030)
    Figure 41. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Type (2019-2030) & (USD/MT)
    Figure 42. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 43. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Application in 2023
    Figure 44. 50-60 Years Old
    Figure 45. 60-70 Years Old
    Figure 46. Others
    Figure 47. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Market Share by Application (2019-2030)
    Figure 48. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Production Value Market Share by Application (2019-2030)
    Figure 49. World Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Average Price by Application (2019-2030) & (USD/MT)
    Figure 50. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Chain
    Figure 51. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Procurement Model
    Figure 52. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Model
    Figure 53. Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Sales Channels, Direct Sales, and Distribution
    Figure 54. Methodology
    Figure 55. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

Related Reports

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 15 Jan 2023

date Pharma & Healthcare

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Supply, Demand and Key Producers, 2023-2029

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Supply, Demand and Key Producers, 2023-2029

date 31 Jan 2023

date Pharma & Healthcare

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 25 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>